Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Demers

Neurological Surgery Reno, NV Medical Doctor

NPI 1427275676 CMS profile 246153

5590 Kietzke Ln, Reno, NV 89511

Open in the dashboard

General payments

$70,738

162 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Demers of Reno, NV is reported in the CMS Open Payments database as having received $70,738 across 162 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30,024 34
2024 General $29,274 50
2023 General $2,594 22
2022 General $6,683 42
2021 General $1,356 11
2020 General $542 1
2019 General $264 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Demers
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Christopher Demers were reported at $30,024. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Christopher Demers Neurological Surgery median Middle half National median
2019 $264 $582 $138–$3,006 $163
2020 $542 $294 $76–$2,174 $114
2021 $1,356 $387 $105–$2,432 $132
2022 $6,683 $542 $139–$2,989 $149
2023 $2,594 $534 $145–$2,697 $160
2024 $29,274 $574 $155–$3,046 $164
2025 $30,024 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $65,849 129 payments
  2. Abbott Laboratories $2,569 17 payments
  3. Centinel Spine, LLC $1,326 9 payments
  4. Globus Medical, Inc. $573 2 payments
  5. DePuy Synthes Sales Inc. $173 1 payment
  6. Medexus Pharma, Inc. $101 1 payment
  7. Edwards Lifesciences Corporation $96 1 payment
  8. Surgical Theater. Inc. $34 1 payment
  9. Theragen, Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $45,140 5 payments
  2. Travel and Lodging $19,681 59 payments
  3. Food and Beverage $5,917 98 payments
Products named General payments · program years 2019–2025
  1. MAZOR X SYSTEM $44,152 64 payments
  2. CD HORIZON SPINAL SYSTEM $5,074 24 payments
  3. PROCLAIM Neuromodulation $1,394 8 payments
  4. PRODISC L $1,203 7 payments
  5. UNID_PASS $1,126 16 payments
  6. STEALTHSTATION S8 PLATFORM $1,074 6 payments
  7. PROCLAIM Neuromodulation $943 1 payment
  8. Excelsius Robotics System $542 1 payment
  9. CONDUIT $173 1 payment
  10. MOUNTAINEER $173 1 payment
  11. Other $1,022 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 107 billing codes

Paid by Medicare

$251,154

Of which drugs: $1,211

Medicare patients

649

Average age 73

Services billed

14,389

351 women, 298 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 73%
High blood pressure 70%
Diabetes 25%
Ischemic heart disease 23%
Depression 23%
Chronic kidney disease 20%
Osteoporosis 19%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadoterate meglumine, 0.1 ml A9575 Office 69 13,000 $1,212

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

162 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record